BioCentury
ARTICLE | Finance

Hard to resist

Why investors in Aragon, Seragon are coming back for thirds with Oric

December 7, 2015 8:00 AM UTC

The team and investors behind drug-resistant cancer companies Aragon Pharmaceuticals Inc. and Seragon Pharmaceuticals Inc. are back for thirds with Oric Pharmaceuticals Inc., which hopes to take a broader approach than its predecessors by focusing on resistance mechanisms in multiple oncology indications rather than in a single tumor type.

Last week, Oric raised $53 million in a series B round with The Column Group, Topspin Partners, OrbiMed, EcoR1, Foresite and Kravis Investment. ...